Liraglutide is more successful in reducing glycated hemoglobin levels to 7% or less regardless of baseline glycated hemoglobin level compared with sitagliptin in adults with type 2 diabetes, said Melanie Davies, MD, MB ChB, professor of diabetes medicine, University of Leicester, United Kingdom.
Liraglutide is more successful in reducing glycated hemoglobin levels to 7% or less regardless of baseline glycated hemoglobin level compared with sitagliptin in adults with type 2 diabetes, said Melanie Davies, MD, MB ChB, professor of diabetes medicine, University of Leicester, United Kingdom.
Davies presented a post hoc analysis of a 26-week, randomized, open-label trial comparing the 2 agents in which she examined the effect of baseline glycated hemoglobin on the level of glycemic control achieved. In the study, 437 patients with type 2 diabetes treated with metformin for at least 3 months and baseline glycated hemoglobin levels of 7.5% to 10.0% were assigned to liraglutide 1.8 mg/day or sitagliptin 100 mg/day. As presented previously, mean A1c levels were reduced by a mean of 1.5% with liraglutide compared with 0.9% with sitagliptin (P1c less than 7% (55% vs 22%, respectively; P)
In the current analysis, patient groups were split into 5 categories according to their baseline glycated hemoglobin levels (≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and >9.0%). The findings across these categories were
At each baseline category of glycated hemoglobin , significantly more liraglutide recipients than sitagliptin recipients achieved an glycated hemoglobin level less than 7%. In the liraglutide group, 85% of those with baseline glycated hemoglobin less than 7.5% achieved their target of 7% or less, and more than 30% in the highest 2 baseline groups achieved their target glycated hemoglobin . By comparison, only 36% of patients with baseline glycated hemoglobin levels less than 7.5% achieved their target with sitagliptin, and less than 20% of those with baseline glycated hemoglobin >8.5% achieved their glycemic target with sitagliptin.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More